content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM 8-K</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15 (d) of the</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities Exchange Act of 1934</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
  October 12, 2013</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">GLOBAL BIOTECH CORP..</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
  charter)</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Delaware</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of incorporation)</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">( Commission file no.)</TD>
      <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">000-33271</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">98-022951</TD></TR>
  </TABLE>
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">2711, CENTREVILLE ROAD, BUREAU 400</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">WILMINGTON, DELAWARE 19808</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 12pt Courier New, Courier, Monospace; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">Company's telephone number,
  including area code:</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">302-288-0658</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0; margin-left: 0"><B>Item 1.01 Entry into
  a Material Definitive Agreement</B></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Courier New, Courier, Monospace">On </FONT>October
  12, 2013<FONT STYLE="font-family: Courier New, Courier, Monospace">, </FONT>Global Biotech Corp.<FONT STYLE="font-family: Courier New, Courier, Monospace">
  (the &ldquo;</FONT>Company&quot; or &quot;Global&quot;) signed a finalized agreement with Purthanol International Ltd. to acquire
  their know-how and all technical aspects of the purthanol extraction process. Further, they have also acquired all purchase orders
  on hand (for forward delivery of purthanol within the next 12 months, or later if agreed to by both parties) and licensing agreements,
  currently signed or in the process of being signed, for the purthanol extraction process. The consideration for all the above
  was 70 million newly issued common shares of Global. A part of said agreement is a non-compete clause with Global.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Item 5.01 </B></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Due to the above listed transaction<B>, </B>Purthanol International
  Ltd. owned 42.5% of the common stock of Global Biotech Corp. As of today&rsquo;s date, December 22, 2013, they own 37.9% of the
  common shares of Global. Louis Pharand, President of Purthanol International Ltd., has already joined Global as its President and
  as a Director. No other significant arrangements or understandings have taken place as regards to this transaction.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>
  
  <P STYLE="font: 12pt Courier New, Courier, Monospace; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Courier New, Courier, Monospace">On </FONT>December
  16, 2013, Global Biotech Corp.<FONT STYLE="font-family: Courier New, Courier, Monospace">(the &ldquo;</FONT>Company&quot; or &quot;Global&quot;)
  signed a finalized agreement with the owner of Biocardel Quebec, a privately held company, to acquire 100% of all outstanding
  shares of that corporation for $5 million, payable $100,000 at signing of the Agreement, $2,400,000 in 9 months, as a balance
  of sale and $2,500,000 in preferred convertible shares of Global. These shares are convertible at a 25% discount to the 90 trading
  -day average sales price of the common shares, whenever Global chooses to exercise the conversion rights. No Officer or Director
  of the acquired company will become an Officer or Director of Global, at present. Biocardel owns a production facility in Richmond,
  Quebec, that turns biologic oil waste products and byproducts into biodiesel fuel, a commodity in demand in both North America
  and Europe.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Signatures</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Pursuant to the requirements of the Securities
  Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Date: December 23, 2013</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Global Biotech Corp.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">By: /s/ Leonard Stella</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Leonard Stella, CEO</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>
  
  
  
  <P STYLE="margin: 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "f8k_globalbio101213.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10459}]
metadata_filer: {"company-data": {"conformed-name": "Global Biotech Corp.", "cik": "0001126162", "assigned-sic": "7389", "irs-number": "980229951", "fiscal-year-end": "0228"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33271", "film-number": "131298487"}, "business-address": {"street1": "2550 BATES RD.", "street2": "SUITE 212", "city": "MONTREAL", "state": "A8", "zip": "H3S 1A7", "phone": "302 288 0658"}, "mail-address": {"street1": "2711 CENTERVILLE", "street2": "SUITE 400", "city": "WILMINGTON", "state": "DE", "zip": "19808"}, "former-company": {"former-conformed-name": "SWORD COMP SOFT CORP", "date-changed": "20001011"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15 (d) of the
  Securities Exchange Act of 1934
  Date of Report (Date of earliest event reported):
  October 12, 2013
  GLOBAL BIOTECH CORP..
  (Exact name of registrant as specified in its
  charter)
  Delaware
  (State or other jurisdiction of incorporation)
  ( Commission file no.)
  (IRS Employer Identification No.)
  000-33271
  98-022951
  2711, CENTREVILLE ROAD, BUREAU 400
  WILMINGTON, DELAWARE 19808
  Company's telephone number,
  including area code:
  302-288-0658
  Item 1.01 Entry into
  a Material Definitive Agreement
  On
  October
  12, 2013
  ,
  Global Biotech Corp.
  (the "
  Company" or "Global") signed a finalized agreement with Purthanol International Ltd. to acquire
  their know-how and all technical aspects of the purthanol extraction process. Further, they have also acquired all purchase orders
  on hand (for forward delivery of purthanol within the next 12 months, or later if agreed to by both parties) and licensing agreements,
  currently signed or in the process of being signed, for the purthanol extraction process. The consideration for all the above
  was 70 million newly issued common shares of Global. A part of said agreement is a non-compete clause with Global.
  Item 5.01
  Due to the above listed transaction
  ,
  Purthanol International
  Ltd. owned 42.5% of the common stock of Global Biotech Corp. As of today's date, December 22, 2013, they own 37.9% of the
  common shares of Global. Louis Pharand, President of Purthanol International Ltd., has already joined Global as its President and
  as a Director. No other significant arrangements or understandings have taken place as regards to this transaction.
  Item 1.01 Entry into a Material Definitive Agreement
  On
  December
  16, 2013, Global Biotech Corp.
  (the "
  Company" or "Global")
  signed a finalized agreement with the owner of Biocardel Quebec, a privately held company, to acquire 100% of all outstanding
  shares of that corporation for $5 million, payable $100,000 at signing of the Agreement, $2,400,000 in 9 months, as a balance
  of sale and $2,500,000 in preferred convertible shares of Global. These shares are convertible at a 25% discount to the 90 trading
  -day average sales price of the common shares, whenever Global chooses to exercise the conversion rights. No Officer or Director
  of the acquired company will become an Officer or Director of Global, at present. Biocardel owns a production facility in Richmond,
  Quebec, that turns biologic oil waste products and byproducts into biodiesel fuel, a commodity in demand in both North America
  and Europe.
  Signatures
  Pursuant to the requirements of the Securities
  Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  Date: December 23, 2013
  Global Biotech Corp.
  By: /s/ Leonard Stella
  Leonard Stella, CEO